BioSpace News Archive

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that its Chief Financial Officer Paul Kim and Chief Commercial Officer Brandon Perthuis are scheduled to virtually participate in the Credit Suisse 29 th Annual Virtual Healthcare Conference on Wednesday, November 11, 2020. These representative

10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the third quarter ended September 30, 2020. Recent Highlights Revenue was $71.8 million for the third quarter, representing a 17% increase over the corresponding period in 2019 and a 67% increase compared to the second quarter of 2020 Completed the acquisitions of ReadCoor and CartaNA, advancing 10x Genomics into In Situ analysis with comprehensive and foundatio

Pacific Biosciences of California, Inc. announced that it intends to offer and sell $85.0 million of shares of its common stock and a selling stockholder intends to offer 1,304,348 of common stock shares in an underwritten public offering.

Amgen (NASDAQ:AMGN) will present at the Cowen 4 th Annual Virtual IO Summit at 3:30 p.m. ET on Friday, November 13, 2020 . David M. Reese , M.D., executive vice president of Research and Development at Amgen will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen’s

BD, a leading global medical technology company, announced its rapid, point-of-care, SARS-CoV-2 antigen test for use on the BD Veritor™ Plus System has been authorized for use by Health Canada under Interim Order.

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the quarter ended September 30, 2020 and highlighted recent corporate progress.

--Expands Clinical Development of Zandelisib to New Indications and Earlier Lines of Treatment-- --MEI Starts Second Fiscal Quarter 2021 with $176.1 Million in Cash--

GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that CEO Rachel King plans to present an overview of the company at the upcoming Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17 and the Jefferies Virtual London Healthcare Conference on Thursday, November 19. Both presentations will be available on the Company’s website, under the Investors tab. Details are as follows: Stifel 2020 Virtual Healthc

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (the “Company” or “Marinus”), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the grant of inducement awards to two (2) new employees. The Compensation Committee of the Board of Directors of Marinus approved the grant of non-qualified stock options to purchase an aggregate of 134,000 shares of its

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will participate in the Stifel 2020 Virtual Healthcare Conference, a fully virtual management access conference, taking place November 16-18. President and Chief Executive Officer, Mark Foley, is scheduled to participate in a virtual fireside chat on Tuesday, N